Science & Enterprise subscription

Follow us on Twitter

  • A biotechnology company is sponsoring university research on light waves reacting in characteristic patterns for de… https://t.co/RG11kdD0as
    about 19 hours ago
  • New post on Science and Enterprise: Univ Lab, Company Developing Phone-Based Virus Sensor https://t.co/Yqq5wZPmqF #Science #Business
    about 19 hours ago
  • A blood test designed for low-resource field settings is shown to quickly detect and distinguish between different… https://t.co/7RCwijmW7N
    about 1 day ago
  • New post on Science and Enterprise: Quick Crispr-Based Test Detects Malaria in Blood https://t.co/LuZnLHRUYW #Science #Business
    about 1 day ago
  • Researchers in the U.K. created a bandage with enhanced human skeletal stem cells that in lab mice repairs simulate… https://t.co/1tD7FxaoRo
    about 2 days ago

Please share Science & Enterprise

Covid-19 Vaccines, Therapies – 3 August 2020

Vaccine and therapy tracker

BioRender Covid-19 vaccine and therapy tracker. (BioRender.com)

3 Aug. 2020. A continuing feature on Science & Enterprise is a weekly statistical report of vaccines and therapies for Covid-19 offered by BioRender, a scientific illustration software company. BioRender, in Toronto, Ontario, develops graphics tools for life sciences, biotechnology, and other disciplines.

Over the past week, seven more therapy candidates entered clinical trials bringing that number to 259, while the number of therapies in development remained the same at 337. And as reported last week, the numbers of vaccine candidates in development and clinical trials show modest but steady growth, now up to 157 and 35 respectively.

In addition to the summary dashboard shown above, the BioRender Covid-19 vaccine and therapy page provides details of the vaccines and therapies, as well as an activity feed showing news updates on these drugs.

A front-page story this morning in the New York Times tells about political pressures on U.S. health agencies to take short cuts to approve a Covid-19 vaccine before the 2020 election in November. These short cuts include bypassing FDA’s advisory committees that review evidence and recommend actions by the agency, an almost unprecedented step for a drug of this magnitude. The implications are immense, including for trust in other vaccines and therapies needing FDA approval.

More from Science & Enterprise:

*     *     *

2 comments to Covid-19 Vaccines, Therapies – 3 August 2020